Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor
出版年份 2016 全文链接
标题
Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor
作者
关键词
-
出版物
DIABETES OBESITY & METABOLISM
Volume 18, Issue 5, Pages 454-462
出版商
Wiley
发表日期
2016-02-26
DOI
10.1111/dom.12652
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes
- (2016) E. Erdmann et al. DIABETES OBESITY & METABOLISM
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS
- (2016) Yehuda Handelsman et al. Endocrine Practice
- Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
- (2016) Walter N. Kernan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers
- (2015) Sreeraj Macha et al. CLINICAL THERAPEUTICS
- Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus
- (2015) Christopher S. Kovacs et al. CLINICAL THERAPEUTICS
- Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin
- (2015) Ralph A. DeFronzo et al. DIABETES CARE
- Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Anne L. Peters et al. DIABETES CARE
- Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data
- (2015) S. Del Prato et al. DIABETES OBESITY & METABOLISM
- Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus
- (2015) C Triplitt et al. EXPERT OPINION ON PHARMACOTHERAPY
- Dapagliflozin Lowers Plasma Glucose Concentration and Improves β-Cell Function
- (2015) Aurora Merovci et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a ‘Case Study’
- (2015) Agata Ptaszynska et al. Diabetes Therapy
- Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a ‘Case Study’
- (2015) Agata Ptaszynska et al. Diabetes Therapy
- Beneficial Effects of Canagliflozin in Combination with Pioglitazone on Insulin Sensitivity in Rodent Models of Obese Type 2 Diabetes
- (2015) Yoshinori Watanabe et al. PLoS One
- Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy
- (2014) Hala Yamout et al. AMERICAN JOURNAL OF NEPHROLOGY
- Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
- (2014) T. Forst et al. DIABETES OBESITY & METABOLISM
- Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis
- (2014) Daniel Levin et al. DIABETOLOGIA
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
- (2014) Aurora Merovci et al. JOURNAL OF CLINICAL INVESTIGATION
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Prevention of Diabetes With Pioglitazone in ACT NOW: Physiologic Correlates
- (2013) R. A. DeFronzo et al. DIABETES
- Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
- (2013) C. S. Kovacs et al. DIABETES OBESITY & METABOLISM
- Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
- (2012) Muhammad A. Abdul-Ghani et al. Current Diabetes Reports
- Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
- (2012) J. Rosenstock et al. DIABETES CARE
- Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin
- (2012) Ö. Ljunggren et al. DIABETES OBESITY & METABOLISM
- Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 2: ST-Segment Elevation Myocardial Infarction
- (2011) David H. Fitchett et al. CANADIAN JOURNAL OF CARDIOLOGY
- Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects
- (2011) S. Sha et al. DIABETES OBESITY & METABOLISM
- Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
- (2011) Muhammad A. Abdul-Ghani et al. ENDOCRINE REVIEWS
- Effect of Thiazolidinediones on Albuminuria and Proteinuria in Diabetes: A Meta-analysis
- (2010) Pantelis A. Sarafidis et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects
- (2010) S. Kasichayanula et al. DIABETES OBESITY & METABOLISM
- Thiazolidinediones and fracture risk in patients with Type 2 diabetes
- (2010) D. J. Betteridge DIABETIC MEDICINE
- Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009
- (2010) R. A. DeFronzo DIABETOLOGIA
- Effects of Pioglitazone on Intramyocellular Fat Metabolism in Patients with Type 2 Diabetes Mellitus
- (2010) Mandeep Bajaj et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
- (2010) Faiez Zannad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients
- (2009) Amalia Gastaldelli et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Thiazolidinedione use and the risk of fractures
- (2009) K. A. Toulis et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
- (2009) R. A. DeFronzo DIABETES
- Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial
- (2009) D. K. Coletta et al. DIABETOLOGIA
- Risk of Fractures with Glitazones
- (2009) Michael Bodmer et al. DRUG SAFETY
- Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors
- (2009) G. Schernthaner INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial
- (2009) Paul M Ridker et al. LANCET
- Impact of peripheral arterial disease in patients with diabetes—Results from PROactive (PROactive 11)
- (2008) J.A. Dormandy et al. ATHEROSCLEROSIS
- Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
- (2008) Y. K. Loke et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Expression of Peroxisome Proliferator-Activated Receptor-γ in Key Neuronal Subsets Regulating Glucose Metabolism and Energy Homeostasis
- (2008) David A. Sarruf et al. ENDOCRINOLOGY
- Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes
- (2008) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started